arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Cytokinetics, Incorporated

CYTK Health Care Biotechnology: Pharmaceutical Preparations
$72.72
Today
as of Sep 4, 16:48 ET
Last 30 days -8.47% Jul 28 → Sep 04
$70.07 $73.11 $76.14 $79.17 $82.21 Jul 28 Aug 05 Aug 12 Aug 20 Aug 27 Sep 04
Open
$73.04
High
$73.84
Low
$72.25
Volume
$1M
Avg Vol
$2M
Mkt Cap
$10.2B
P/E (TTM)
—
Beta
—
52w High
$88.31
52w Low
$47.22
Div Yield
—
Shares Out
—

Recent Press Releases & News last 60 days · 25 items

Sep 2 · 20:00 PR GlobeNewswire
Cytokinetics to Participate in September Investor Conferences
Sep 2 · 18:30 Zacks
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Sep 1 · 21:01 MT Newswires
Cytokinetics Insider Sold Shares Worth $357,400, According to a Recent SEC Filing
▸ Show all 25 press releases & news Free account →

Overview

52-week range
$47
$88
62% of range
Avg surprise (last 3)
+6.7%
Avg reaction (last 2)
+4.7%
50% positive
Latest IV / EM
46%
EM ±7.3% · $75 · Sep 18

Earnings trends

EPS — actual vs estimate Actual Estimate
$-2.55$-2.19$-1.83$-1.48$-1.12 Actual $-1.38Actual $-1.34Actual $-1.35Actual $-1.33Actual $-1.31Actual $-1.36Actual $-1.36Est $-1.41Actual $-1.12Est $-1.34Actual $-2.55Actual $-1.67Est $-1.67Actual $-1.50 MarJunSepMarJunSepMar/2025Jun/2025SepMar/2026Jun
Revenue vs Net Income Revenue Net income
$-306M$-212M$-118M$-24M$70M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.50 — — — — financials
Tue May 5, 2026Mar/2026 $-1.67 $-1.67 0.0% -22.8% +16.7% earnings
Tue Sep 30, 2025Sep 2025 $-2.55 — — — — financials
Thu Aug 7, 2025Jun/2025 $-1.12 $-1.34 +16.4% — — earnings
Tue May 6, 2025Mar/2025 $-1.36 $-1.41 +3.5% — -7.4% earnings
Mon Sep 30, 2024Sep 2024 $-1.36 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.31 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.33 — — — — financials
Sat Sep 30, 2023Sep 2023 $-1.35 — — — — financials
Fri Jun 30, 2023Jun 2023 $-1.34 — — — — financials
Fri Mar 31, 2023Mar 2023 $-1.38 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$29M$19M—$2M$67M$2M—$463,000
Cost of revenue————————
Gross profit————————
Operating income$-179M$-184M—$-167M$-112M$-156M—$-141M
Net income$-199M$-206M—$-306M$-134M$-161M—$-161M
EPS (diluted)$-1.50$-1.67—$-2.55$-1.12$-1.36—$-1.36

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$255M$130M$123M$225M$75M$74M$95M$47M
Inventory$380,000$154,000$0—————
Total current assets$1.21B$839M$917M$977M$887M$956M$1.11B$1.02B
Total assets$1.92B$1.27B$1.42B$1.44B$1.23B$1.26B$1.40B$1.44B
Long-term debt$248M$247M$246M$159M$159M$92M$93M$93M
Total liabilities$2.10B$2.10B$2.08B$1.96B$1.59B$1.53B$1.54B$1.45B
Total equity$-173M$-827M$-660M$-521M$-369M$-266M$-135M$-14M

Implied volatility — last 90 days

34%53%72%91%110% Jun 07 — IV 52% · EM ±7.2%Jun 08 — IV 49% · EM ±6.5%Jun 09 — IV 53% · EM ±6.6%Jun 10 — IV 57% · EM ±6.7%Jun 11 — IV 50% · EM ±5.6%Jun 12 — IV 41% · EM ±4.2%Jun 15 — IV 52% · EM ±3.7%Jun 16 — IV 60% · EM ±3.6%Jun 17 — IV 90% · EM ±3.8%Jun 19 — IV 44% · EM ±9.8%Jun 22 — IV 45% · EM ±9.4%Jun 23 — IV 42% · EM ±8.6%Jun 24 — IV 40% · EM ±8.1%Jun 25 — IV 41% · EM ±8.0%Jun 26 — IV 38% · EM ±7.3%Jun 29 — IV 45% · EM ±8.1%Jun 30 — IV 42% · EM ±7.2%Jul 01 — IV 41% · EM ±6.8%Jul 02 — IV 41% · EM ±6.6%Jul 03 — IV 42% · EM ±6.6%Jul 06 — IV 50% · EM ±6.9%Jul 07 — IV 43% · EM ±5.7%Jul 08 — IV 45% · EM ±5.6%Jul 09 — IV 50% · EM ±5.9%Jul 10 — IV 46% · EM ±5.1%Jul 13 — IV 87% · EM ±7.2%Jul 14 — IV 66% · EM ±4.8%Jul 15 — IV 84% · EM ±4.9%Jul 16 — IV 74% · EM ±3.1%Jul 20 — IV 50% · EM ±11.9%Jul 21 — IV 65% · EM ±15.1%Jul 22 — IV 62% · EM ±14.2%Jul 23 — IV 50% · EM ±11.4%Jul 24 — IV 52% · EM ±11.6%Jul 27 — IV 56% · EM ±11.8%Jul 28 — IV 57% · EM ±11.6%Jul 29 — IV 53% · EM ±10.7%Jul 30 — IV 48% · EM ±9.4%Jul 31 — IV 61% · EM ±11.7%Aug 03 — IV 63% · EM ±11.2%Aug 04 — IV 61% · EM ±10.5%Aug 05 — IV 50% · EM ±8.3%Aug 06 — IV 68% · EM ±11.0%Aug 07 — IV 52% · EM ±8.1%Aug 10 — IV 47% · EM ±6.5%Aug 11 — IV 55% · EM ±7.3%Aug 12 — IV 43% · EM ±5.4%Aug 13 — IV 45% · EM ±5.3%Aug 14 — IV 37% · EM ±4.1%Aug 17 — IV 68% · EM ±5.7%Aug 18 — IV 70% · EM ±5.1%Aug 19 — IV 72% · EM ±4.3%Aug 20 — IV 111% · EM ±4.6%Aug 24 — IV 46% · EM ±9.5%Aug 25 — IV 53% · EM ±10.9%Aug 26 — IV 44% · EM ±8.8%Aug 27 — IV 41% · EM ±8.0%Aug 28 — IV 45% · EM ±8.6%Aug 31 — IV 43% · EM ±7.5%Sep 01 — IV 43% · EM ±7.4%Sep 02 — IV 35% · EM ±5.8%Sep 03 — IV 42% · EM ±6.7%Sep 04 — IV 46% · EM ±7.3%

Sector peers

LLY
Eli Lilly and Company
$1.1T $1,148.00-0.1%
JNJ
Johnson & Johnson
$671.0B $275.71+0.2%
ABBV
AbbVie Inc.
$430.9B $256.50+0.1%
MRK
Merck & Company, Inc.
$317.1B $150.33+0.0%
PM
Philip Morris International Inc
$299.3B $182.53+0.0%
NVS
Novartis AG
$297.9B $155.11-3.0%
View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in